Breadcrumb

[A16-48] Sofosbuvir/velpatasvir (chronic hepatitis C) - Benefit assessment according to §35a SGB V

Overview

Overview

Commission: Commission awarded on 2016-07-13 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 591 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A16-73] Sofosbuvir/velpatasvir (chronic hepatitis C) - Addendum to Commission A16-48
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2016-10-17 Extract of dossier assessment 591 kBPDFdownload file
2016-10-17 Dossier assessment (German version) 2 MBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Sofosbuvir/velpatasvir (chronic hepatitis C) - Benefit assessment according to §35a SGB V [PDF, 591 kB]

Federal Joint Committee (G-BA)

2017-01-05 A G-BA decision was published.

G-BA documents on this decision

Press releases

2016-10-17 Sofosbuvir/velpatasvir in chronic hepatitis C: hint of added benefit in two of ten subindications



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close